← Back to Search

At-risk patients for which an alert is sent during the intervention phase for Deep Vein Thrombosis (eVTE Trial)

N/A

Waitlist Available

Research Sponsored by Scott C. Woller, MD

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Patient age ≥ 18 years

The encounter must be inpatient

Timeline

Screening 3 weeks

Treatment Varies

Follow Up from discharge to 7 days after discharge

Awards & highlights

eVTE Trial Summary

This trial is testing a new algorithm that uses patient age and blood test results to identify patients who may benefit from a blood thinner to decrease their risk of blood clots. The trial will evaluate the use

Who is the study for?

This trial is for patients recently discharged from the hospital who are at high risk of developing blood clots, such as deep vein thrombosis or pulmonary embolism, but have a low risk of bleeding. Specific eligibility criteria details were not provided.Check my eligibility

What is being tested?

The study tests if an EHR alert about prescribing rivaroxaban to reduce blood clot risks affects clinician behavior and patient outcomes. Hospitals will activate this alert in monthly blocks to compare results.See study design

What are the potential side effects?

While specific side effects are not detailed here, common side effects of rivaroxaban include bleeding complications, dizziness, headache, elevated liver enzymes, and allergic reactions.

eVTE Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am 18 years old or older.

Select...

My medical care requires staying in the hospital.

eVTE Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ from discharge to 7 days after discharge

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~from discharge to 7 days after discharge

This trial's timeline: 3 weeks for screening, Varies for treatment, and from discharge to 7 days after discharge for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

(implementation)

Primary clinical efficacy outcome (effectiveness)

Primary clinical safety outcome

eVTE Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: At-risk patients for which an alert is sent during the intervention phaseExperimental Treatment1 Intervention

Patients found to be at an increased risk for VTE but a low risk for bleeding (based upon eVTE risk assessment), thereby meeting criteria for alerting during the intervention phase

Group II: At-risk patients during the baseline phaseActive Control1 Intervention

Patients found to be at an increased risk for VTE but a low risk for bleeding (based upon eVTE risk assessment), and who meet criteria for alerting, but for whom no alert is sent during the baseline phase

0 / 2Eligibility criteria met

Find a Location

Who is running the clinical trial?

Janssen PharmaceuticalsIndustry Sponsor

80 Previous Clinical Trials

53,071 Total Patients Enrolled

Scott C. Woller, MDLead Sponsor

1 Previous Clinical Trials

48 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Which individuals are eligible to participate in this clinical study?

"Candidates who are between the ages of 18 and 110 years old, and have been diagnosed with deep vein thrombosis (DVT), are eligible to participate in this study. The trial aims to enroll approximately 152,000 candidates."

Answered by AI

Are individuals aged 40 and above eligible to participate in this clinical trial?

"Individuals aged 18 and above, but not exceeding the age of 110, are eligible for participation in this study."

Answered by AI

Are there ongoing efforts to actively enroll patients in this clinical trial?

"According to the information provided on clinicaltrials.gov, this particular trial is currently not enrolling patients. Its initial posting date was March 1st, 2024, and it was last edited on January 29th, 2024. However, there are currently 261 other ongoing clinical trials that are actively recruiting participants at this time."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Alerting Providers at Patient Hospital Discharge to Consider Prescribing Rivaroxaban to Reduce Venous Thromboembolism

Scott C. Woller, MD 2024. "Alerting Providers at Patient Hospital Discharge to Consider Prescribing Rivaroxaban to Reduce Venous Thromboembolism". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06232551.

All > Pulmonary Embolism > Xarelto